⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29033484 | 1.00 | — | — | |
| SCHEMBL357919 | 1.00 | — | — | |
| SCHEMBL9885441 | 1.00 | — | — | |
| SCHEMBL978384 | 1.00 | — | — | |
| SCHEMBL48728 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL743531 | 0.96 | — | — | |
| Hydrochloric Acid SCHEMBL1265950 | 0.96 | — | — | |
| Hydrochloric Acid SCHEMBL742834 | 0.96 | — | — | |
| Hydrochloric Acid SCHEMBL6034020 | 0.96 | — | — | |
| Hydrochloric Acid SCHEMBL48034 | 0.96 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 303 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113493628-A | Quantum dot ink and preparation method of quantum dot film | TCL科技集团股份有限公司 | 2021-10-12 | — | — | CN | claimed |
| CN-113122053-A | Quantum dot ink and preparation method of quantum dot film | TCL集团股份有限公司 | 2021-07-16 | — | — | CN | claimed |
| US-20030187051-A1 | Anticholesterol agents, cardiovascular disorders, hypotensive agents, antidiabetic agents, antitumor agents | PFIZER INC. | 2003-10-02 | — | — | US | claimed |
| EP-4436667-B1 | PIPERAZINYLSULFONYLARYL COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS | HOFFMANN LA ROCHE (CH) | 2026-01-21 | — | — | EP | disclosed |
| US-20250179059-A1 | ANTICANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-06-05 | — | — | US | disclosed |
| US-20250115571-A1 | OXOPIPERAZINE DERIVATIVES | Inthera Bioscience AG (CH) | 2025-04-10 | — | — | US | disclosed |
| US-20250011300-A1 | PIPERAZINYLSULFONYLARYL COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS | HOFFMANN-LA ROCHE INC. (US) | 2025-01-09 | — | — | US | disclosed |
| US-12162870-B2 | Anticancer compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-12-10 | — | — | US | disclosed |
| WO-2024220543-A1 | NK3 MODULATORS AND USES THEREOF | KALLYOPE, INC. (US) | 2024-10-24 | — | — | WO | disclosed |
| EP-4436667-A1 | PIPERAZINYLSULFONYLARYL COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS | F. Hoffmann-La Roche AG (CH) | 2024-10-02 | — | — | EP | disclosed |
| US-20240239774-A1 | SOLUBLE ADENYLYL CYCLASE (SAC) INHIBITORS AND USES THEREOF | CORNELL UNIVERSITY (US) | 2024-07-18 | — | — | US | disclosed |
| CN-1305477-A | Azablicyclic 5-HT, receptor ligands | PFIZER PROD INC (US) | 2001-07-25 | — | — | CN | disclosed |
| WO-2001040217-A1 | NOVEL BENZOIMIDAZOLE DERIVATIVES USEFUL AS ANTIPROLIFERATIVE AGENTS | PFIZER PRODUCTS INC. (US) | 2001-06-07 | — | — | WO | disclosed |
| US-6130338-A | OXIDATING THE CORRESPONDING 3-PYRROLINE COMPOUND TO GIVE AN EPOXYPYRROLIDINE COMPOUND | TORAY INDUSTRIES, INC. (JP) | 2000-10-10 | — | — | US | disclosed |
| US-6090805-A | Tocolytic oxytocin receptor antagonists | MERCK & CO., INC. (US) | 2000-07-18 | — | — | US | disclosed |
| EP-0985664-A2 | Method of producing pyrrolidine derivatives | TORAY INDUSTRIES, INC. (JP) | 2000-03-15 | — | — | EP | disclosed |
| US-5264204-A | Hydrophilic free radicals for magnetic resonance imaging | MALLINCKRODT MEDICAL, INC. (US) | 1993-11-23 | — | — | US | disclosed |
| WO-1993022662-A1 | HYDROPHILIC FREE RADICALS FOR MAGNETIC RESONANCE IMAGING | MALLINCKRODT MEDICAL, INC. (US) | 1993-11-11 | — | — | WO | disclosed |
| US-4585785-A | HYPOTENSIVES, ANTIDEPRESSANTS | A. H. ROBINS COMPANY, INC. (US) | 1986-04-29 | — | — | US | disclosed |
| US-4452809-A | ANTIARRHYMIA, HYPOTENSIVE AGENTS | A. H. ROBINS COMPANY, INC. (US) | 1984-06-05 | — | — | US | disclosed |